$2.41T
Total marketcap
$72.71B
Total volume
BTC 50.95%     ETH 14.91%
Dominance

Cytek Biosciences, Inc. 8EQ.F Stock

3.4 EUR {{ price }} 0.000000% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
959.46M EUR
LOW - HIGH [24H]
3.4 - 3.4 EUR
VOLUME [24H]
200 EUR
{{ volume }}
P/E Ratio
0
Earnings per share
-0.09 EUR

Cytek Biosciences, Inc. Price Chart

Cytek Biosciences, Inc. 8EQ.F Financial and Trading Overview

Cytek Biosciences, Inc. stock price 3.4 EUR
Previous Close 7.6 EUR
Open 7.8 EUR
Bid 7.8 EUR x N/A
Ask 8.05 EUR x N/A
Day's Range 7.8 - 7.8 EUR
52 Week Range 6.2 - 15.6 EUR
Volume 200 EUR
Avg. Volume 3 EUR
Market Cap 1.06B EUR
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -0.09 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 27 EUR

8EQ.F Valuation Measures

Enterprise Value 790.03M EUR
Trailing P/E N/A
Forward P/E 70.909096
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 6.3724117
Price/Book (mrq) 2.4983985
Enterprise Value/Revenue 4.758
Enterprise Value/EBITDA -106.617

Trading Information

Cytek Biosciences, Inc. Stock Price History

Beta (5Y Monthly) N/A
52-Week Change -11.73%
S&P500 52-Week Change 20.43%
52 Week High 15.6 EUR
52 Week Low 6.2 EUR
50-Day Moving Average 8.69 EUR
200-Day Moving Average 11.08 EUR

8EQ.F Share Statistics

Avg. Volume (3 month) 3 EUR
Avg. Daily Volume (10-Days) 0 EUR
Shares Outstanding 135.67M
Float 91.5M
Short Ratio N/A
% Held by Insiders 17.06%
% Held by Institutions 55.10%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -1.44%
Operating Margin (ttm) -6.087%
Gross Margin 61.32%
EBITDA Margin -4.46%

Management Effectiveness

Return on Assets (ttm) -1.25%
Return on Equity (ttm) -0.52%

Income Statement

Revenue (ttm) 166.06M EUR
Revenue Per Share (ttm) 1.23 EUR
Quarterly Revenue Growth (yoy) 5.80%
Gross Profit (ttm) 100.97M EUR
EBITDA -7410000 EUR
Net Income Avi to Common (ttm) -2394000 EUR
Diluted EPS (ttm) -0.01
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 299M EUR
Total Cash Per Share (mrq) 2.2 EUR
Total Debt (mrq) 17.26M EUR
Total Debt/Equity (mrq) 4.08 EUR
Current Ratio (mrq) 7.531
Book Value Per Share (mrq) 3.122

Cash Flow Statement

Operating Cash Flow (ttm) -7893000 EUR
Levered Free Cash Flow (ttm) -31802124 EUR

Profile of Cytek Biosciences, Inc.

Country Germany
State CA
City Fremont
Address 47215 Lakeview Boulevard
ZIP 94538
Phone 877 922 9835
Website https://cytekbio.com
Industry Medical Devices
Sector(s) Healthcare
Full Time Employees 682

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Q&A For Cytek Biosciences, Inc. Stock

What is a current 8EQ.F stock price?

Cytek Biosciences, Inc. 8EQ.F stock price today per share is 3.4 EUR.

How to purchase Cytek Biosciences, Inc. stock?

You can buy 8EQ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cytek Biosciences, Inc.?

The stock symbol or ticker of Cytek Biosciences, Inc. is 8EQ.F.

Which industry does the Cytek Biosciences, Inc. company belong to?

The Cytek Biosciences, Inc. industry is Medical Devices.

How many shares does Cytek Biosciences, Inc. have in circulation?

The max supply of Cytek Biosciences, Inc. shares is 282.2M.

What is Cytek Biosciences, Inc. Price to Earnings Ratio (PE Ratio)?

Cytek Biosciences, Inc. PE Ratio is now.

What was Cytek Biosciences, Inc. earnings per share over the trailing 12 months (TTM)?

Cytek Biosciences, Inc. EPS is -0.09 EUR over the trailing 12 months.

Which sector does the Cytek Biosciences, Inc. company belong to?

The Cytek Biosciences, Inc. sector is Healthcare.